Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-16T11:31:35.063Z Has data issue: false hasContentIssue false
  • English
  • Français

HLA Antigens in Schizophrenia: Differences between Patients with and without Evidence of Brain Atrophy

Published online by Cambridge University Press:  29 January 2018

Daniel Luchins ,
E. Fuller Torrey ,
Daniel R. Weinberger ,
Steven Zalcman ,
Lynn Delisi ,
Armead Johnson ,
Nicholas Rogentine  and
Richard Jed Wyatt
Daniel Luchins
Affiliation:
Laboratory of Clinical Psychopharmacology, National Institute of Mental Healthy WAW Bldg. St Elizabeths Hospital, Washington, DC
E. Fuller Torrey
Affiliation:
Noyes Division, St Elizabeths Hospital, Washington, DC
Daniel R. Weinberger
Affiliation:
Laboratory of Clinical Psychopharmacology
Steven Zalcman
Affiliation:
Laboratory of Clinical Psychopharmacology
Lynn Delisi
Affiliation:
Laboratory of Clinical Psychopharmacology
Armead Johnson
Affiliation:
Division of Immunology, Department of Microbiology, Duke University Medical School, Durham, NC
Nicholas Rogentine
Affiliation:
Immunology Branch, National Cancer Institute, Bethesda, Md
Richard Jed Wyatt
Affiliation:
Laboratory of Clinical Psychopharmacology
Get access Rights & Permissions [Opens in a new window]

Summary

A survey of 14 published studies found no consistent association between specific HLA antigens and schizophrenia. Since these studies lacked diagnostic or biological criteria, an investigation was undertaken using recognized diagnostic criteria and CT scan findings. Typing for HLA antigens at loci A, B and C was carried out on 130 patients. Among 92 black schizophrenic patients there was an increase of HLA-A2 which remained significant even after correcting for the number of antigens studied. When the patients for whom CT scans were available were divided according to the presence or absence of evidence of brain atrophy, there was an increase of A2 in the black schizophrenic patients without evidence of atrophy, which remained significant after multiplying by the number of antigens studied. However, there was no significant increase of A2 in those with evidence of atrophy. Similar trends held for the white population but they failed to reach significance. The need for HLA studies on biologically defined groups of schizophrenic patients is stressed.

Type
Papers
Information
The British Journal of Psychiatry , Volume 136 , Issue 3 , March 1980 , pp. 243 - 248
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

∗ Amos, D. B. & Pool, B. (1976) HLA typing. Manual of Clinical Immunology (ed. N. R. Rose). American Society for Microbiology.Google Scholar
Bennahum, D. A., Troup, G. M., Rada, R. T., Kellner, R. & Kyner, W. T. (1977) HLA antigens in schizophrenia and manic depressive mental disorders. Clinical Research, 25, 114.Google Scholar
Bodmer, W. F., Jones, E. A., Barnstable, C. J. & Bodmer, J. G. (1978) Genetics of HLA: the major histocompatibility systems. Proceedings of the Royal Society of London, 202, 93–116.Google Scholar
Book, J. A., Wettenberg, L. & Modrzewska, (1979) Schizophrenia in a north Swedish geographic isolate 1900–1977. 4th International Catecholamine Symposium (eds. E. Usdin, I. Kopin and J. Barchos). Oxford: Pergamon Press.Google Scholar
Cazzullo, C. L., Smeraldi, E. & Penati, G. (1974) The leucocyte antigenic system HL-A as a possible genetic marker of schizophrenia. British Journal of Psychiatry, 125, 25–7.Google Scholar
Eberhard, G., Fránzen, G. & Löw, B. (1975) Schizophrenia susceptibility and HL-A antigens. Neuropsychobiology, 1, 211–7.CrossRefGoogle Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archive of General Psychiatry, 26, 57–63.Google Scholar
Iványi, D., Zemek, P., Iványi, P. (1976) HLA antigens in schizophrenia. Tissue Antigens, 8, 217–20.Google Scholar
Iványi, P., Iványi, D. & Zemek, P. (1977) HLA-Cw4 in paranoid schizophrenia. Tissue Antigens, 9, 41–4.CrossRefGoogle ScholarPubMed
Iványi, D., Zemek, P. & Iványi, P. (1978) HLA antigens as possible markers of heterogeneity in schizophrenia. Journal of Immunogenetics 5, 165–72.Google ScholarPubMed
Johnstone, E., Crow, T. J., Frith, C. D., Husband, J. & Kreel, L. (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet, iii, 924–6.Google Scholar
Julien, R. A., Mercier, P. & Chouragqui, (1977) Schizophrenia and the HLA system. Evidence for increase in A9 and Cw4 in paranoid schizophrenics. Annates Medico-Psychologiques, 135, 939–44.Google Scholar
Kyner, W. T., Bennahum, D. A., Troup, G. M., Rada, R. T. & Kellner, R. (1978) The HLA-SD antigens and schizophrenia—A statistical analysis. In Neurochemical and Immunologic Components in Schizophrenia (ed. D. Bergsma and A. L. Goldstein). New York: Alan R. Liss Inc.Google Scholar
McDevitt, H. O. & Bodmer, W. F. (1974) HL-A, immune-response genes, and disease. Lancet, i, 1269–75.Google Scholar
McGuffin, P., Farmer, A. E. & Rajah, S. M. (1978) Histocompatibility antigens and schizophrenia. British Journal of Psychiatry, 132, 149–51.CrossRefGoogle ScholarPubMed
Mercier, P., Sutter, J. M., Julien, R. A. & Kieffer, N. (1977) Schizophrenia: Association of the paranoid form and antigens HLA-A9 and B5. Encéphale, 49–53.Google Scholar
National Institute of Allergic and Infectious Disease (1976) MAID Tissue Typing Techniques. DHEW publications, NIM–76–545.∗∗ Google Scholar
Smeraldi, E., Bellodi, L., Scorza-Smeraldi, R., Fabio, J. & Sacchetti, E. (1976a) HLA-SD antigens and schizophrenia: statistical and genetical considerations. Tissue Antigens, 8, 191–6.Google Scholar
Smeraldi, E., Bellodi, L. & Cazzullo, C. L. (1976b) Further studies on the major histocompatibility complex as a genetic marker for schizophrenia. Biological Psychiatry, 11, 655–61.Google ScholarPubMed
Smeraldi, E., Bellodi, L., Sacchetti, E. & Cazzullo, C. L. (1976c) The HLA system and clinical response to treatment with chlorpromazine. British Journal of Psychiatry, 129, 486–9.CrossRefGoogle ScholarPubMed
Spitzer, R. L., Endicott, J. & Robins, E. (1977) Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders. Third Edition. New York Psychiatric Institute.Google Scholar
Weinberger, D. R., Torrey, E. F. & Wyatt, R. J. (1979a) Cases of cerebellar atrophy in a group of chronic schizophrenic patients. Lancet, i, 718.Google Scholar
Weinberger, D. R., Torrey, E. F., Neophytides, A. N. & Wyatt, R. J. (1979b) Lateral cerebral ventricular enlargement in chronic schizophrenia. Archives of General Psychiatry, 36, 735–39.Google Scholar
Weinberger, D. R., Torrey, E. F., Neophytides, A. N. & Wyatt, R. J. (1979c) Structural abnormalities of the cerebral cortex in chronic schizophrenia. Archives of General Psychiatry, 36, 935–9.Google Scholar
World Health Organization (1972) International Pilot Study of Schizophrenia, Geneva, WHO.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.